Details for Patent: 8,747,896

Which drugs does patent 8,747,896 protect, and when does it expire?

Patent 8,747,896 protects SITAVIG and is included in one NDA.

This patent has thirty-two patent family members in twenty-seven countries.

Summary for Patent: 8,747,896

Title:	Mucosal bioadhesive slow release carrier for delivering active principles
Abstract:	A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
Inventor(s):	Costantini; Dominique (Paris, FR), Lemarchand; Caroline (Paris, FR)
Assignee:	BioAlliance Pharma (Paris, FR)
Application Number:	13/565,653
Patent Claim Types: see list of patent claims	Formulation; Delivery; Use;

Drugs Protected by US Patent 8,747,896

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Epi Hlth	SITAVIG	acyclovir	TABLET;BUCCAL	203791-001	Apr 12, 2013		RX	Yes	Yes			Y			TREATMENT OF HERPES LABIALIS

Foreign Priority and PCT Information for Patent: 8,747,896

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	06290480	Mar 24, 2006

International Family Members for US Patent 8,747,896

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	060085
Austria	446743
Australia	2007231029
Brazil	PI0709057
Canada	2647123